

# Blue Gen Therapeutics Foundation to Present at the ASRS Annual Scientific Meeting

SACRAMENTO, CA, UNITED STATES, May 20, 2024 /EINPresswire.com/ -- Blue Gen Therapeutics Foundation, a 501(c)(3) California non-profit clinical-stage biotech, is dedicated to advancing gene therapy treatments for Blue Cone Monochromacy and Achromatopsia. The foundation announced the presentation of pre-clinical IND enabling data for BGTF-027, a novel intravitreal gene therapy for the treatment of Blue Cone



Monochromacy, at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The meeting will be held in Stockholm, Sweden, from July 17-20, 2024. This announcement coincides with International Blue Cone Monochromacy Awareness Day, highlighting a rare inherited retinal disease affecting approximately 25,000 males in the US and Europe.

ASRS Annual Scientific Meeting Presentation Information:

Title: Preclinical Evaluation of BGTF-027 (AAV 7m8-L-opsin), A Novel Intravitreal Gene Therapy for the Treatment of Blue Cone Monochromacy

Date/Time: Friday, July 19, 2024, at 9:13 AM CEST

Presenter: Szilárd Kiss, M.D., The Bob and Dolores Hope-Robert M. Ellsworth, M.D. Distinguished Professor of Ophthalmology

The presentation will be available on the website: [www.bgtfoundation.org](http://www.bgtfoundation.org) shortly after the event.

About Blue Gen Therapeutics Foundation:

Blue Gen Therapeutics Foundation is a 501(c)(3) California non-profit clinical-stage biotech dedicated to advancing gene therapy treatments for rare inherited retinal diseases. BGTF focuses on utilizing adeno-associated virus (AAV) based intravitreal gene therapies for the treatment of Blue Cone Monochromacy and Achromatopsia, providing crucial solutions to these

rare inherited retinal diseases that severely impact vision.

The foundation has secured an exclusive global license for ADVN-062 (now BGTF-027) and ADVN-082, two innovative intravitreal gene therapies, from Adverum Biotechnologies. These programs utilize Adverum's proprietary AAV.7m8 capsid.

For media inquiries, please contact: [Info@bgtfoundation.org](mailto:Info@bgtfoundation.org).

John Cavitt

Blue Gen Therapeutics Foundation

+1 916-245-4689

[email us here](#)

Visit us on social media:

[Facebook](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/712515776>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.